Perioperative-or-Surgery-Alone Decision Aid for Cisplatin-Ineligible Bladder Cancer

A visit-time tablet tool for newly diagnosed muscle-invasive bladder cancer patients who cannot take cisplatin, showing the quantified choice between going straight to cystectomy or adding perioperative enfortumab vedotin plus pembrolizumab: 2-year event-free survival of 74.7% vs 39.4% and a 57.1% vs 8.6% chance the tumor is completely gone at surgery, against severe side effects in 71.3% vs 45.9% and roughly a year of treatment.